Get notified when NUVB files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Removed Risk Disclosures

  • Derivative Lawsuit Disclosure Removed (removed) — The prior filing disclosed an active derivative lawsuit against directors over excessive compensation; the current filing omits this disclosure entirely.
NYSE: NUVB Nuvation Bio Inc. 10-Q

Nuvation Bio revenue surges 555.6% to $31.7M, but net loss widens 6.5% to $62.8M

Filed August 6, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 7, 2025 · ~1 min read

Key Changes

  • high

    Total revenue jumped 555.6% to $31.7M, driven by IBTROZI U.S. sales of $23.2M in Q2 and a $58.7M Eisai upfront payment.

    MD&A: Revenue verify on EDGAR →
  • high

    Net loss widened 6.5% to $62.8M despite a 20% narrower operating loss, as non-operating/other expense rose $16.4M.

    Key Financials view on EDGAR →
  • high

    Completed a $287.5M convertible notes offering in July 2026, using $58.7M to repay Sagard debt and incurring a $9.5M loss on extinguishment.

    MD&A: Financing verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.

Partner

Trade NUVB commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov View full financials on EDGAR ↗

Figures/quotes linked to EDGAR · Narrative written by AI · Sep 26, 2026 · How we verify